Table 1

Characteristics of breast cancer patients with poor-prognosis disease (transplant cohort)

VariableHFE genotype
≥1 C282Y allelean = 15 (n, %)bWt/Wt n = 26 (n, %)b
Mean age at diagnosis in years (range)50.1 (36–54)48 (36–59)
Premenopausal at diagnosisc8 (53)19 (73)
Primary reason for BCTd
 Breast cancer1524
 Secondary malignancy11
Limited stage at diagnosise13 (87)23 (88)
Metastatic disease at diagnosis3 (20)2 (8)
Tumor size at diagnosis
 <5.0 cm8 (46)15 (58)
 ≥5.0 cm4 (27)9 (34)
 N/A4 (27)2 (8)
ER ± PR tumor expression
 Positive11 (73)18 (69)
 Negative4 (27)7 (27)
 N/A0 (0)1 (4)
Lymph node involvement at staging
 ≤5 LN+6 (40)8 (35)
 >5 LN+8 (53)17 (65)
 N/A1 (7)0 (0)
Mean time from diagnosis to BCT years (range)2.8 (1–8)2.0 (0–14)
Smoking7 (47)7 (27)
Chemotherapy cycles (mean no., range)8 (4–13)6 (4–16)
Chemotherapeutic agents (mean no., range)4 (2–6)8 (2–6)
  • a ≥1 C282Y allele, homozygotes + heterozygotes; Wt/Wt, homozygous wild-type.

  • b All Ps for comparisons between genotype groups were insignificant (>0.05).

  • c Ovarian function present.

  • d BCT, blood cell transplantation; ER/PR, estrogen receptors/progesterone receptors; N/A, data not available; LN, lymph node(s).

  • e Includes two cases of inflammatory breast cancer.